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licenseThe savior of binge drinkers: Another liver tonic from a common
vegetable?1. Study of hepatoprotective effect of Solanum nigrum in
this issue of JCMA
The liver is the organ that metabolizes nutrients and
xenobiotics, and it is susceptible to injury by various toxins
and metabolites. Alcohol liver disease (ALD) is one of the
most common liver diseases around the globe. Although
numerous efforts have been undertaken to combat this global
health burden, there is no therapeutic modality to date for
patients with ALD. In this issue of JCMA, Liu et al1 show that
aqueous extracts from Solanum nigrum have hepatoprotective
effects against ethanol-induced liver injury based on in vitro
and in vivo animal models. The study was well-conducted and
produced solid results and is the first study about S. nigrum
focusing on the prevention of alcohol-related liver damage.
Since S. nigrum is a common vegetable consumed worldwide,
we are intrigued as to whether S. nigrum can be efficacious as
a liver tonic to combat ALD.
2. S. nigrum as food and herbal medicine
Although parts of S. nigrum can be toxic to humans, it has
been utilized as food or as a medicinal herb worldwide for
thousands of years.2 The plant has a long history of medicinal
usage, dating back to ancient Greece. Additionally, it is a
traditional European herb used as a sudorific, analgesic, and
sedative with narcotic properties.
S. nigrum is also an important herb used in traditional
Indian medicine, where it is incorporated into treatments for
dysentery, gastrointestinal diseases, and fever. The juice of the
plant is also used on ulcers and other skin diseases, and the
fruits are used as a tonic, laxative, and appetite stimulant and
for treating asthma. S. nigrum is a widely used plant in oriental
medicine, where it is considered to be antitumorigenic, anti-
oxidant, anti-inflammatory, hepatoprotective, diuretic, and
antipyretic.2
3. Hepatoprotective effects of S. nigrum
The protective effects of the aqueous or ethanol extract of
S. nigrum have been demonstrated in carbon tetrachloridex.doi.org/10.1016/j.jcma.2015.10.003
901/Copyright © 2015, the Chinese Medical Association. Published by El
(http://creativecommons.org/licenses/by-nc-nd/4.0/).(CCl4)-induced liver injury in rats.
3 The effect of S. nigrum
extract has also been evaluated on thioacetamide (TAA)-
induced liver fibrosis in mice.4 Histological examination
suggested that S. nigrum can reduce the degree of fibrosis
caused by TAA treatment.4 S. nigrum can also decrease cad-
mium chloride (CdCl2)-induced hepatotoxicity in rats.
5 These
studies suggest that S. nigrum could protect the liver against
CCl4-, TAA-, and CdCl2-induced liver injury in rats. Hep-
atotoxicity induced by different toxins may have some com-
mon pathways, but differences still exist between them.
Ethanol-induced liver injury seems more complicated than
toxin-related hepatic damage. A two- or three-hit theory has
been proposed as the pathogenesis of ALD and nonalcoholic
fatty liver disease. However, there had been no published study
about the cytoprotective effect of S. nigrum against ALD until
Liu et al’s1 article was published in this issue of JCMA.4. Merit of Liu et al's1 study
This is a well-designed controlled study using mice and
hepatocytes harvested from mice as the S. nigrum therapeutic
targets to prevent ethanol insult.1 Multiple biomarkers of
hepatocyte injury were used to assess the hepatoprotective
effect of S. nigrum. These included alanine aminotransferase
(ALT), aspartate aminotransferase (AST), malondialdehyde,
superoxide dismutase, glutathione peroxidase, and glutathione
S-transferase A1 (GSTA1).1 It has been shown that S. nigrum
has the dose-effective capacity to mitigate the hepatocyte
damage presented in all biomarkers, in addition to evidence of
histology of the liver. The result of this study is crucial in the
elucidation of the underlying mechanism of S. nigrum in
relation to its hepatoprotective effect against ethanol. The
authors emphasized that GSTA1 can be an early predictor of
hepatocyte injury, compared with the conventional tests of
liver enzymes ALT and AST.1,6 The role of GSTA1 in the early
detection of liver injury is intriguing in the field of drug-
induced liver injury (DILI) since the application of genetic
markers and other biomarkers of DILI is time-consuming and
they typically have low sensitivity and specificity.7 However,
relevant articles about GSTA1 in acute liver injury are scarce,sevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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are warranted.
5. Limitations of this study
Although Liu et al's1 study has demonstrated the mecha-
nism and potential hepatoprotective role of S. nigrum in
ethanol-induced liver injury using the hepatocyte and mice
model, is it time to encourage consuming more S. nigrum as a
liver tonic before an alcohol binge? The answer is no. Hun-
dreds of vegetables and herbs have been shown to have some
hepatoprotective effects in earlier studies of cytomolecular
levels and animal models. However, no one vegetable or herb
has efficacy in the diverse liver diseases, such as chronic
hepatitis B, chronic hepatitis C, and alcoholic hepatitis. There
is still a wide gap between the circumstances of a bench study
and clinical application in the biopharmaceutical science
community and industry. Accordingly, virtually all medicinal
herbs cannot be successfully demonstrated to have proven
efficacy and safety as an authentic drug.
Furthermore, aqueous extracts from S. nigrum purchased
from Harbin Jiacheng Science and Technology Development
Co. (Harbin, China) were used in the present study.1 However,
no further details about the components of these aqueous
extracts were described. S. nigrum possesses various com-
pounds responsible for diverse activities. The major active
components are glycoalkaloids, glycoproteins, and poly-
saccharides, but S. nigrum also contains polyphenolic com-
pounds, such as gallic acid, catechin, protocatechuic acid,
caffeic acid, epicatechin, rutin, and naringenin.2 The glyco-
alkaloids include solamargine, solasonine, and solanine, which
belong to the tropane group of compounds. In fact, the func-
tion and activity of solanine have been extensively studied,
and it is found to comprise 95% of the total alkaloid con-
centration present in the S. nigrum plant.2 Whether the hep-
atoprotective effect in this study is from the crude extract or
from just one component of S. nigrum is unknown. This is the
major drawback of this kind of biopharmaceutical study.
6. Toxicity of S. nigrum
Most species in the Solanaceae family may be poisonous to
humans as well as to livestock.2 Although S. nigrum is con-
sidered to be an edible plant, its toxicity is mainly due to the
presence of solanine, a glycol-alkaloid causing varying
degrees of toxicity in a dose-dependent manner.2 Most of the
presented toxic symptoms/signs are the anticholinergic effect
of alkaloids, including nausea, vomiting, diarrhea, headache,
dizziness, slurred speech, fever, sweating, tachycardia, dilation
of pupils, blindness, mental confusion, convulsions, coma, and
even death.2 The amount of toxic alkaloid in a plant depends
on the climate, soil type, season, and maturity. The green
unripe berries are generally considered more toxic than the
ripe berries.2 Therefore; it is probable that by boiling the plant,
the toxic components are destroyed given that the plant is
reported to be edible after cooking.In conclusion, S. nigrum is a widely used plant incorporated
into herbal medicine and food and possessing various char-
acteristics, such as antitumorigenic, antioxidant, anti-
inflammatory, hepatoprotective, and antipyretic activity. Liu
et al's study1 as referenced in this issue of JCMA used in vitro
and in vivo mice models to assess the hepatoprotective effect
of S. nigrum on ALD. They found S. nigrum can protect the
integrity of hepatocytes and thus reduce the release of liver
GSTA1. However, it is still premature to suggest the con-
sumption of S. nigrum as a liver tonic to prevent alcohol
hepatitis because of the potential anticholinergic toxic effect
of this plant and the lack of evidence or clinical data to vali-
date its efficacy and safety in ALD. Boiling this vegetable is
suggested to avoid toxicity. However, to examine a more
expanded clinical application of S. nigrum, this plant with its
wide-ranging therapeutic properties needs to be investigated in
well-designed clinical studies.
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